Curevac
Sort by
2 items
Filter
-
The Wall Street Journal - Business
GSK, CureVac Expand Licensing Agreement
GSK struck a deal to buy the rights to CureVac’s Covid-19 and flu vaccines for up to $1.56 billion, in a bid to regain ground lost to newcomers to the vaccine market during the pandemic. -
MarketWatch - Business
CureVac’s stock soars on GSK’s $1.56 billion deal for its COVID-19 and flu vaccines
U.K. pharmaceutical giant GSK said the deal gives it the rights to develop, manufacture and commercialize messenger RNA-based candidate vaccines for flu and COVID-19.